tiprankstipranks
Trending News
More News >
LNA Sante SA (FR:LNA)
:LNA
Advertisement

LNA Sante SA (LNA) AI Stock Analysis

Compare
4 Followers

Top Page

FR:LNA

LNA Sante SA

(LSE:LNA)

Rating:70Outperform
Price Target:
€34.00
▲(5.59% Upside)
LNA Sante SA's overall stock score is driven by strong financial performance and a solid valuation. The company's ability to generate cash and maintain stable operational margins supports its financial health. However, technical indicators suggest the stock may be overbought, which could impact short-term price movements. The absence of recent earnings call data and corporate events limits additional insights.

LNA Sante SA (LNA) vs. iShares MSCI France ETF (EWQ)

LNA Sante SA Business Overview & Revenue Model

Company DescriptionLNA Sante SA (LNA) is a prominent player in the healthcare sector, primarily focused on providing high-quality care and support services for the elderly and those requiring long-term care. The company operates a network of nursing homes, rehabilitation centers, and assisted living facilities across various regions. LNA is committed to enhancing the quality of life for its residents through personalized care plans, skilled nursing services, and innovative health management solutions.
How the Company Makes MoneyLNA generates revenue through multiple key streams, primarily from the provision of residential care services in its nursing homes and assisted living facilities. The company charges fees for accommodation, daily care, and specialized medical services, which are often covered by governmental health programs or private insurance. Additionally, LNA may engage in partnerships with local health authorities and institutions, which can provide funding and resources for its operations. The organization also benefits from economies of scale, allowing it to optimize operational efficiencies and reduce costs, further enhancing its profitability.

LNA Sante SA Financial Statement Overview

Summary
LNA Sante SA shows consistent revenue growth and stable operational margins. The high leverage on the balance sheet presents some risk, but strong cash flow generation supports financial flexibility.
Income Statement
72
Positive
LNA Sante SA has shown consistent revenue growth over the years, with a notable increase from 2023 to 2024. The gross profit margin has weakened compared to previous years, which could indicate rising costs or pricing pressures. However, the EBIT and EBITDA margins remain stable, suggesting operational efficiency. The net profit margin shows a slight decline, which could be a concern if it continues.
Balance Sheet
65
Positive
The company's debt-to-equity ratio is relatively high, reflecting significant leverage. However, the return on equity has been stable, indicating effective use of shareholder funds. The equity ratio is moderate, suggesting a balanced capital structure. Overall, the balance sheet exhibits some risk due to high debt levels, but equity growth is positive.
Cash Flow
78
Positive
LNA Sante SA has demonstrated strong operating cash flow relative to net income, highlighting efficient cash generation. The free cash flow growth has been positive, supporting future investments or debt reduction. The free cash flow to net income ratio is healthy, indicating good cash availability after capital expenditures.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue806.60M736.09M728.22M689.49M573.89M
Gross Profit91.10M241.09M622.42M577.87M481.03M
EBITDA144.85M144.63M141.82M131.64M108.17M
Net Income21.82M23.41M25.81M23.51M7.81M
Balance Sheet
Total Assets1.54B1.51B1.51B1.53B1.50B
Cash, Cash Equivalents and Short-Term Investments75.06M77.17M101.98M152.12M121.39M
Total Debt876.44M887.67M911.55M1.00B971.50M
Total Liabilities1.21B1.20B1.21B1.31B1.30B
Stockholders Equity313.81M299.24M289.33M216.09M188.65M
Cash Flow
Free Cash Flow71.24M84.56M89.86M65.98M132.74M
Operating Cash Flow82.06M97.50M103.20M79.92M146.50M
Investing Cash Flow-23.93M-15.69M-41.99M-27.65M-205.94M
Financing Cash Flow-60.22M-106.69M-110.88M-21.53M40.24M

LNA Sante SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price32.20
Price Trends
50DMA
25.98
Positive
100DMA
24.52
Positive
200DMA
24.06
Positive
Market Momentum
MACD
1.60
Negative
RSI
68.94
Neutral
STOCH
80.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:LNA, the sentiment is Positive. The current price of 32.2 is above the 20-day moving average (MA) of 27.96, above the 50-day MA of 25.98, and above the 200-day MA of 24.06, indicating a bullish trend. The MACD of 1.60 indicates Negative momentum. The RSI at 68.94 is Neutral, neither overbought nor oversold. The STOCH value of 80.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:LNA.

LNA Sante SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€755.53M20.8716.07%2.49%-1.38%-22.98%
70
Outperform
€319.90M14.397.12%4.05%9.58%-6.69%
57
Neutral
€1.61B-1.70%1.98%85.87%
55
Neutral
€1.11B-6.74%5.79%-575.58%
54
Neutral
€4.18B13.09-41.26%2.55%14.43%-26.74%
53
Neutral
€87.95M
44.34%-27.37%
51
Neutral
€2.16B0.02-22.82%8.43%-102.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:LNA
LNA Sante SA
30.70
7.01
29.57%
FR:EQS
Equasens
50.30
3.57
7.64%
FR:GDS
Ramsay Generale de Sante
10.05
-4.80
-32.32%
FR:CLARI
Clariane
4.51
2.53
128.24%
FR:EMEIS
Orpea SA
13.40
3.59
36.61%
FR:MAAT
MaaT Pharma
5.46
-1.88
-25.61%

LNA Sante SA Corporate Events

LNA Santé Achieves 2024 Targets Amidst Healthcare Challenges
Mar 26, 2025

LNA Santé reported strong financial results for 2024, meeting its targets despite challenges in the healthcare sector. The company achieved a 6.7% increase in operating sales and a 7.7% rise in net operating profit, while managing its debt effectively. The company plans to continue its growth trajectory in 2025, targeting a 6% increase in operating sales and focusing on strategic acquisitions and facility transformations to meet healthcare demands.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 07, 2025